a Manchester Royal Eye Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre , Manchester , UK.
b University of Manchester , Manchester , UK.
Ocul Immunol Inflamm. 2018;26(7):997-1004. doi: 10.1080/09273948.2017.1294185. Epub 2017 Mar 20.
To assess the outcomes of intravitreal benzyl alcohol-free triamcinolone acetonide suspension in uveitis-related macular oedema.
Single-center retrospective cohort study of 66 injections to 44 eyes of 40 patients. Uveitis diagnosis, systemic and local therapy, intraocular pressure (IOP), central retinal thickness (CRT), number of injections, time to re-injection and side-effects were noted during 6-months minimum follow-up.
Sixty eight percent of eyes received a single injection. 18% required 2 injections, and 13% received ≥3 injections with mean time to second and third injections of 25.5 and 52.7 weeks, respectively. 90% of injections were unilateral. Mean CRT reduced, and by 12-weeks visual acuity improvement >0.3logMar was achieved in 46%. Cataract progression (47%) and IOP>21 mmHg (45%) were the commonest adverse events.
Preservative-free triamcinolone is an additional option for uveitis-related macular oedema, particularly in unilateral cases, with favorable CRT and visual outcomes. Repeat injections may be necessary, and the period of efficacy varies between eyes.
评估玻璃体内注射无苯甲醇的曲安奈德混悬液治疗葡萄膜炎相关黄斑水肿的疗效。
这是一项单中心回顾性队列研究，共纳入 40 名患者的 44 只眼，共接受了 66 次注射。在 6 个月的最低随访期内，记录了葡萄膜炎的诊断、全身和局部治疗、眼内压（IOP）、中心视网膜厚度（CRT）、注射次数、再次注射时间和不良反应。
68%的患眼接受了单次注射，18%需要 2 次注射，13%接受了≥3 次注射，第二次和第三次注射的平均时间分别为 25.5 和 52.7 周。90%的注射为单侧。平均 CRT 降低，46%的患眼在 12 周时视力提高≥0.3logMar。白内障进展（47%）和 IOP>21mmHg（45%）是最常见的不良反应。
无防腐剂的曲安奈德是治疗葡萄膜炎相关黄斑水肿的另一种选择，特别是在单侧病例中，具有良好的 CRT 和视力结果。可能需要重复注射，并且不同患眼的疗效持续时间不同。
